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KIBRA is associated with 
accelerated cognitive decline and 
hippocampal atrophy in APOE ε4-
positive cognitively normal adults 
with high Aβ-amyloid burden
Tenielle Porter1,2, Samantha C. Burnham3,4, Vincent Doré5,6, Greg Savage7, Pierrick Bourgeat5, 
Kimberly Begemann1, Lidija Milicic1, David Ames8,9, Ashley I. Bush  10, Paul Maruff10,11,  
Colin L. Masters10, Christopher C. Rowe6,12, Stephanie Rainey-Smith4, Ralph N. Martins4,13, 
David Groth14, Giuseppe Verdile4,14, Victor L. Villemagne6,10,12 & Simon M. Laws  1,2,14
A single nucleotide polymorphism, rs17070145, in the KIdney and BRAin expressed protein (KIBRA) 
gene has been associated with cognition and hippocampal volume in cognitively normal (CN) 
individuals. However, the impact of rs17070145 on longitudinal cognitive decline and hippocampal 
atrophy in CN adults at greatest risk of developing Alzheimer’s disease is unknown. We investigated 
the impact rs17070145 has on the rate of cognitive decline and hippocampal atrophy over six years 
in 602 CN adults, with known brain Aβ-amyloid levels and whether there is an interactive effect with 
APOE genotype. We reveal that whilst limited independent effects of KIBRA genotype were observed, 
there was an interaction with APOE in CN adults who presented with high Aβ-amyloid levels across 
study duration. In comparison to APOE ε4-ve individuals carrying the rs17070145-T allele, significantly 
faster rates of cognitive decline (global, p = 0.006; verbal episodic memory, p = 0.004), and hippocampal 
atrophy (p = 0.04) were observed in individuals who were APOE ε4 + ve and did not carry the 
rs17070145-T allele. The observation of APOE effects in only non-carriers of the rs17070145-T allele, in 
the presence of high Aβ-amyloid suggest that carriers of the rs17070145-T allele are conferred a level of 
resilience to the detrimental effects of high Aβ-amyloid and APOE ε4.
In cognitively normal older individuals, high levels of neocortical amyloid-β (Aβ-amyloid) are associated with 
subtle but detectable cognitive decline1 and hippocampal atrophy2. This observation is consistent with models of 
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Alzheimer’s disease (AD) which propose a protracted preclinical phase that could take up to 20 years3. This pro-
vides a period of opportunity for understanding, and even interfering with, AD pathogenesis and thus the iden-
tification of biological factors, or trait characteristics, that themselves can influence AD progression has become 
of increased importance.
Several genes have been associated with cognitive performance, particularly episodic memory, and hippocam-
pal atrophy. Previous studies have associated genetic polymorphisms, in particular apolipoprotein E (APOE) ε2/
ε3/ε4 genotype (see review4,5) and the non-synonymous rs6265 (Val66Met) SNP in brain derived neurotropic 
factor (BDNF)6–9, with altered rates of episodic memory decline and hippocampal atrophy. Decline in measures 
of episodic memory, modified by genetic variation, have been reported in both the healthy elderly10 and those 
predicted to be in the early stages of AD based on neocortical Aβ-amyloid imaging6,7,11. These findings raise the 
potential that other genetic factors may also moderate the toxic effects of Aβ-amyloid early in AD and contribute 
to altered rates of cognitive decline and hippocampal atrophy.
One such candidate is the gene encoding the KIdney and BRAin expressed protein (KIBRA; sometimes 
referred to as WW domain-containing protein 1 (WWC1))12. KIBRA is a cytoplasmic, signal transducer protein 
expressed mainly in the kidney and brain13 and in vitro experiments suggest that, through reduction in post-
synaptic levels, it mediates tau induced memory loss and disruption of synaptic plasticity14. This in vitro data is 
supported through genetic studies that report the association of allelic variation in the KIBRA gene with memory 
performance, hippocampal atrophy and measurable differences in brain activation. Specifically, a substitution of 
C for T in the 9th intron (rs17070145), was initially identified through a GWAS of verbal episodic memory perfor-
mance and replicated in two additional independent cohorts12. Episodic memory is one of the earliest cognitive 
domains to decline, with previous studies observing decline 4–8 years prior to executive function and up to 7–10 
years prior to other cognitive domains15–17.
However, there is a lack of consensus in subsequent studies that attempted to replicate these genetic associa-
tions with memory performance. Cross-sectional studies of cognitively normal (CN) older adults, carriage of the 
rs17070145-T allele has been associated with better performance in episodic memory18–22, delayed recall23–25 and 
spatial learning26 and increased hippocampal volume20 and activity19,24. Conversely, several studies have either 
associated the absence of rs17070145-T with better semantic27 and long-term28 memory, executive function29 
and overall cognitive performance30 or were unable to show any association of the SNP with cross sectional 
episodic memory29,31–33 and hippocampal volume31 or longitudinal decline in episodic memory and hippocam-
pal volume31. However, common to all these studies is the lack of inclusion of Aβ-amyloid imaging, which may 
contribute to the lack of consensus due to the impact of underlying Aβ-amyloid burden on cognition not being 
considered1,6,7,11.
To address this conjecture requires the availability of comprehensive longitudinal data from the prospec-
tive cohort studies of AD, such as the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study, which offers 
the opportunity to retrospectively evaluate candidate biological factors (e.g. genetic variation) to determine the 
impact on progression of AD related phenotypes, such as cognitive decline and hippocampal atrophy. The AIBL 
Study has now more than six years of serial cognitive and neuroimaging assessments, including Aβ-amyloid and 
structural imaging, in a group of CN adults collected at 18-month intervals. Therefore, the aim of this study was to 
characterize, through reporting on 6-years of longitudinal data, the role of KIBRA rs17070145 allelic variation in 
this highly characterised CN adult sample and examine the extent to which this allelic variation is associated with 
Aβ-amyloid related cognitive decline and atrophy of the hippocampus. The hypothesis was that CN adults who 
carry the rs17070145-T allele would show a slower rate of memory decline and hippocampal atrophy than those 
not carrying this allele, though this relationship would be dependent on the presence of a high brain Aβ-amyloid 
burden and interact with APOE genotype.
Results
The effect of KIBRA on cognition and hippocampal atrophy in cognitively normal adults. A 
total of 602 CN older adults, defined through the AIBL battery of clinical and neuropsychological assess-
ments34 were included in this study. As shown in Table 1 there were no significant differences or trends between 
rs17070145 (henceforth referred to simply as KIBRA) T carriers and non-T carriers at baseline with respect to 
demographic variables, premorbid intellect, depressive symptoms, or genotype. In the initial analysis, co-varied 
for APOE ε4 carrier and Aβ-amyloid status (classified by being above (Αβhigh) or below (Αβlow) Positron Emission 
Tomography (PET) Aβ-amyloid tracer-specific thresholds) there were no significant differences in the trajectories 
between T carriers and non-carriers for measures of global cognition or episodic memory amongst CN adults 
(Supplementary Figure 1, Supplementary Table 1). However, there was a trend towards T-carriers having a mild 
improvement (0.028 standard deviations (SD)/year) in both global cognition (non-T carriers, −0.025 SD/year; 
p = 0.051) and verbal episodic memory (non-T carriers, −0.019 SD/year; p = 0.085), likely due to a practice effect. 
When evaluating the effect of KIBRA on hippocampal atrophy in all cases, and co-varying for APOE ε4 carrier 
and Aβ-amyloid status, no significant difference (p = 0.242) was observed between T carriers (−0.017 cm3/year), 
and non-T carriers (−0.026 cm3/year) over six years (Supplementary Figure 1, Supplementary Table 1). Further, 
no significant differences were observed at baseline in any measures of cognition or hippocampal volume.
No significant differences were observed at baseline in either measure of cognition or hippocampal volume 
when investigating the Aβ × KIBRA × Time interaction. Relative to Αβlow/KIBRA T carriers, the Αβhigh/KIBRA 
non-T carrier group showed a significantly greater rate of decline in global cognition (0.037 SD/year; −0.085 SD/
year; p = 0.008, q = 0.036), and the verbal episodic memory (0.033 SD/year; −0.080 SD/year; p = 0.012, q = 0.042) 
(Fig. 1, Table 2). However, no statistical difference was seen between Αβhigh/KIBRA T carriers and Αβlow/KIBRA 
non-T carriers. Analysis of hippocampal atrophy revealed that relative to Αβlow/KIBRA T carriers (−0.015 cm3/
year), the Αβhigh/KIBRA non-T carrier group (−0.055 cm3/year) showed a significantly greater rate of hippocam-
pal atrophy (p = 0.002, q = 0.034) over six years (Fig. 1, Table 2). Likewise, this trajectory of hippocampal atrophy 
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was also significantly different (p = 0.009, q = 0.034) relative to Αβlow/KIBRA non-T carriers (−0.017 cm3/year). 
In contrast, Αβhigh/KIBRA T carriers’ rate of atrophy did not differ from the Αβlow groups.
The effect of KIBRA on cognition and hippocampal atrophy in cognitively normal adults with 
high Aβ-amyloid. No significant differences were observed in Αβhigh CN adults at baseline in either meas-
ure of cognition or hippocampal volume when investigating the APOE × KIBRA × Time interaction. Relative 
to APOE ε4-ve/KIBRA T carriers, the APOE ε4 + ve/KIBRA non-T carrier group showed a significantly greater 
rate of decline in global cognition (p = 0.006, q = 0.034) and verbal episodic memory (p = 0.004, q = 0.034) over 
six years (Fig. 2, Table 3). Further, relative to APOE ε4 + ve/KIBRA T carriers, the APOE ε4 + ve/KIBRA non-T 
carrier group showed a nominally significantly greater rate of decline on the verbal episodic memory compos-
ite, however after FDR correction this remained only a strong trend (p = 0.018, q = 0.055) over six years (Fig. 2, 
Table 3). Hippocampal atrophy analysis revealed that relative to APOE ε4-ve/KIBRA T carriers (−0.016 cm3/
year), the APOE ε4 + ve/KIBRA non-T carrier group (−0.067 cm3/year) had nominally significantly different 
rates of hippocampal atrophy however did not survive correction for multiple testing (p = 0.040, q = 0.107) over 
six years (Fig. 2, Table 3). This trajectory of hippocampal atrophy was suggestive of being different to APOE 
ε4-ve/KIBRA non-T carriers (−0.006 cm3/year), however this did not reach significance (p = 0.125), even though 
this trajectory showed negligible difference to APOE ε4-ve/KIBRA T carriers. APOE ε4 + ve/KIBRA T carriers’ 
rate of atrophy did not differ from the APOE ε4-ve groups. To ascertain that these differences in rates of decline 
were not due to disproportionate rates of clinical conversion, the frequency of individuals who converted to Mild 
Cognitive Impairment (MCI) or AD over the course of the study was investigated. Within the APOE ε4 + ve 
group there was no significant difference (p = 0.43) between KIBRA non-T carriers (0.294, 15 out of 41) and 
KIBRA T carriers (0.294, 10 out of 34) in terms of clinical conversion.
Discussion
The data reported here support the hypothesis that KIBRA genotype, in combination with APOE ε4 and 
Aβ-amyloid, affects rates of memory decline and hippocampal atrophy in cognitively normal adults. In those 
CN adults with high Aβ-amyloid burden at baseline, KIBRA non-T carriers showed significantly faster decline 
in the statistically driven global composite, and verbal episodic memory when compared to T carriers with low 
Aβ-amyloid burden. Within the subset of CN adults with high Aβ-amyloid burden, we showed that those who 
are APOE ε4 + ve and KIBRA non-T carriers had significantly faster rates of decline in verbal episodic memory 
over 6 years, compared to APOE ε4 + ve/KIBRA T carrier and both APOE ε4-ve groups. Importantly, minimal 
decline was also observed in the APOE ε4 + ve/KIBRA T carrier group, suggesting that carriage of the KIBRA 
T allele imparts a level of resilience to negative effects of APOE ε4 and Aβ-amyloid on memory performance. 
Further, between group comparisons of the rates of clinical conversion (CN > MCI/AD) over the course of the 
study revealed no significant differences, suggesting that the faster rates of decline were not due to a higher rate 
of clinical conversion.
This is further supported by the observations that rates of hippocampal atrophy in this study also differ based 
on KIBRA genotype. In CN adults Aβ-amyloid has been previously reported to be associated with increased 
hippocampal atrophy2,35,36, however in this study this was only observed in those individuals who did not possess 
the KIBRA T-allele, whilst in contrast KIBRA T-carriers’ rate of atrophy did not significantly differ from the Αβlow 
groups. In a meta-analysis of APOE neuroimaging studies, hippocampal atrophy has been shown to be increased 
in APOE ε4 carriers5. Here we report that this association, in a group of Αβhigh CN individuals, was again only 
observed in those individuals who did not possess the KIBRA T-allele, whilst in contrast APOE ε4 + ve/KIBRA 
T-carriers’ rate of atrophy did not differ from the APOE ε4-ve groups. Taken together, we propose that the KIBRA 
T allele affords carriers a level of resilience to the detrimental effects of Aβ-amyloid and APOE ε4 allele on neuro-
degeneration, specifically hippocampal atrophy.
Overall n = 602
KIBRA T carrier 
n = 335
KIBRA non-T 
carrier n = 267 p
Age (years) 70.79 (6.55) 70.73 (6.49) 70.72 (6.41) 0.9788
Female (%) 334 (55.48) 188 (56.12) 146 (54.68) 0.7871
Years of Education
0–8 48 (8.00) 27 (8.08) 21 (7.89)
0.9419
9–12 222 (37.00) 127 (38.02) 95 (35.71)
13–15 126 (21.00) 69 (20.66) 57 (21.43)
15+ 204 (34.00) 111 (33.23) 93 (34.96)
Premorbid IQ (FSIQ) 107.86 (7.23) 107.66 (7.28) 108.14 (7.30) 0.4311
Depressive Symptoms (GDS) 1.05 (1.28) 1.05 (1.35) 1.04 (1.18) 0.9156
APOE ε4 carriage (%) 165 (27.97) 84 (25.53) 81 (31.03) 0.1655
High Aβ-amyloid burden (%) 145 (24.09) 76 (22.69) 69 (25.84) 0.4215
MRI (n) 548 301 247 NA
Table 1. Demographic Information. Baseline demographic and clinical characteristics of all imaged cognitively 
normal adults in the AIBL study, and based on KIBRA rs17070145 T carriage (T_T and C_T) and non-carriage 
(C_C). p values represent statistical significance when comparing T carriage and non-carriage. GDS, Geriatric 
Depression Scale; FSIQ, Wechsler Adult Intelligence Scale 3rd Edition (WAIS-III) Full Scale Intelligence Quotient.
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The findings presented herein are in line with the original study12 and subsequent reports linking the KIBRA T 
allele with resilience in episodic memory performance18–21,24. The absence of replication by other studies27–29,31–33 
may be in part due to the lack of consistency in the measures of memory decline, whereby varying single neu-
ropsychological tests, aiming to measure a certain feature of memory or cognition, were used. The use in this cur-
rent study of a combination of global and episodic memory composite scores, which encompass several different 
tests best associated with a cognitive construct, could also have contributed to the ability to detect associations 
with the KIBRA genotype. However, the lack of inclusion of an assessment of underlying Aβ-amyloid burden 
in the previous studies may in fact be the more telling contributor to the lack of consensus on the association of 
KIBRA with cognitive performance. The level of neocortical Aβ-amyloid is associated with differential rates of 
cognitive decline1,37, and this is further altered by genetic factors, in particular APOE10,11 and BDNF6,7. Accounting 
for the underlying Aβ-amyloid burden in the current study may have further contributed to the detection of dif-
ferences in rates of cognitive decline and hippocampal atrophy reported with APOE ε4 and KIBRA.
Whilst the incorporation of cognitive composites and accounting for underlying Aβ-amyloid burden is 
considered a strength of this study, the following limitations of the study are acknowledged. Firstly, the use of 
different cognitive tests individually or in combination for the calculation of domain composites, then those spe-
cifically described in this study and using the methodology described herein, may yield different results. Second, 
this study included 6-years of longitudinal follow-up and validation in other longitudinal cohorts, not under-
taken herein, over longer durations of follow-up, may result in different findings. Third, the cognitively normal 
participants in this study were volunteers and not selected at random from the community, they were generally 
well educated and performed well on cognitive assessments and as such the findings presented herein may be 
applicable only to similar cohorts. Fourth, there is an overlap between those who are Aβhigh  and those who are 
APOE ε4 + ve, which could confound the results when looking at their interaction. Finally, the KIBRA T-allele’s 
previously reported association with altered brain activation using fMRI12,19 could not be tested due to the lack of 
fMRI data, under a non-resting state, in the AIBL Study.
Figure 1. Rates of change in cognitively normal adults based on KIBRA T carriage and Aβ-amyloid status. 
Rates of change are presented for (a) a statistically driven global composite, (b) a verbal episodic memory 
composite, and (c) hippocampal atrophy (n = 548) in cognitively normal adults (n = 602 unless otherwise 
stated). Αβlow, low Αβ-amyloid burden; Αβhigh, high Αβ-amyloid burden. Αβlow/KIBRA T carriers (green), 
Αβlow/KIBRA non-T carriers (blue), Αβhigh/KIBRA T carriers (orange), Αβhigh/KIBRA non-T carriers (red), 
controlling for APOE ε4 carrier status. Hippocampal atrophy analysis also controlled for gender (shading 
represents time dependent standard error, *p < 0.05 when comparing to the Αβlow/KIBRA T carrier group, 
^p < 0.05 when comparing to the Αβlow/KIBRA non-T carrier group, ϕp < 0.05 when comparing to the 
Αβhigh/KIBRA T carrier).
Αβlow KIBRA T 
carrier n = 259
Αβlow KIBRA non-T 
carrier n = 198
Αβhigh KIBRA T 
carrier n = 76
Αβhigh KIBRA non-T 
carrier n = 69
β β β β
Global 0.037 −0.006 −0.012 −0.085*
Verbal Episodic 
Memory 0.033 0.0004 0.005 −0.080*
Hippocampal Atrophy −0.015 −0.017 −0.026 −0.055*^
Table 2. Group slopes for cognitive composites and hippocampal atrophy in all imaged cognitively normal 
participants by KIBRA carrier and Αβ-amyloid status. Group slopes for cognitive composites (presented in 
SD/year; n = 602) and hippocampal atrophy (presented in cm3/year; n = 548) in all imaged cognitively normal 
participants, controlling for APOE ε4 carrier status. Αβlow, low Αβ-amyloid burden; Αβhigh, high Αβ-amyloid 
burden. *p < 0.05 when comparing to the Αβlow/KIBRA T carrier (T_T and C_T) group, ^p < 0.05 when 
comparing to the Αβlow/KIBRA non-T carrier group, ϕp < 0.05 when comparing to the Αβhigh/KIBRA T carrier.
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Studies have previously demonstrated the main areas of KIBRA expression in the brain are those also that are 
implicated in memory function, the hippocampus and temporal cortex12,38. Furthermore, increased KIBRA gene 
expression in the temporal cortex39 and hippocampus22 has been associated with late onset AD. However, in a 
recent post-mortem brain transcriptomic study in neuropathogically normal individuals by Piras and colleagues 
a trend towards increased KIBRA gene expression was observed in KIBRA T homozygotes40. Further quantitative 
PCR analysis reported an over-expression in T-homozygotes compared to C-homozygotes in the hippocampus40. 
Further, the transcriptomic analysis revealed differential activation of the MAPK pathway40, a pathway impor-
tant in learning and memory processes, suggesting a potential mechanism underpinning a decline in memory 
performance reported in this study. It has also been shown that there is increased hippocampal activity in epi-
sodic memory performance tasks in KIBRA T carriers when compared with non-T carriers19, consistent with the 
notion of protection from memory decline. KIBRA T allele carriers have also been shown to have a decreased 
levels of brain activation compared to non-T allele carriers in several hippocampal regions activated during mem-
ory retrieval12. The authors hypothesised that individuals who do not carry the T allele require a greater level of 
hippocampal activation for memory retrieval12.
In addition to the association studies described above, recent in vivo evidence provides molecular insights 
into mechanisms by which KIBRA is involved in memory performance. Synaptic plasticity, which is altered in 
AD, is modulated by dendrin, which in turn binds to the protein that KIBRA encodes (KIBRA; see review41). 
Further, KIBRA protein contains a protein kinase C (isoform ζ; PKCζ) binding domain42 and has been reported 
to co-localise with protein kinase M (isoform ζ; PKMζ)43, a brain specific variant of PKCζ, which plays impor-
tant roles in memory formation and long-term potentiation. Johannsen et al. have shown the function of the 
KIBRA protein to be regulated by its C2 domain38, which is required for Ca2+ binding and is therefore involved 
in signal transduction in the neurons. This regulation is hypothesised to mediate the effect of the KIBRA protein 
on memory formation38. In a recent study, Tracy and colleagues have proposed a novel mechanism by which 
acetylated tau associated memory loss and disruption of synaptic plasticity is mediated by a reduction in postsyn-
aptic KIBRA protein14. This finding links the previous reports of reduced KIBRA gene expression in AD with a 
biological mechanism mediated by acetylated tau. Whether the KIBRA T allele affords a level of resilience to this 
loss of synaptic plasticity remains to be determined.
Figure 2. Rates of change in cognitively normal adults with high Aβ-amyloid burden. Rates of change 
are presented for (a) a statistically driven global composite, (b) a verbal episodic memory composite, (c) 
hippocampal atrophy in cognitively normal adults with high Aβ-amyloid (n = 145). APOE ε4-negative/KIBRA 
T carriers (green), APOE ε4-ve/KIBRA non-T carriers (blue), APOE ε4 + ve/KIBRA T carriers (orange), APOE 
ε4 + ve/KIBRA non-T carriers (red). Hippocampal atrophy analysis controlled for gender (shading represents 
time dependent standard error, *p < 0.05 when comparing to the APOE ε4-ve/KIBRA T carrier group, ^p < 0.05 
when comparing to the APOE ε4-ve/KIBRA non-T carrier group, ϕp < 0.05 when comparing to the APOE 
ε4 + ve/KIBRA T carrier).
APOE ε4-ve KIBRA 
T carrier n = 38
APOE ε4-ve KIBRA 
non-T carrier n = 27
APOE ε4 + ve KIBRA 
T carrier n = 34
APOE ε4 + ve KIBRA 
non-T carrier n = 40
β β β β
Global −0.016 −0.014 −0.063 −0.163*^†
Verbal Episodic 
Memory −0.008 −0.019 −0.031 −0.146*^
ϕ†
Hippocampal Atrophy −0.016 −0.006 −0.034 −0.067*
Table 3. Group slopes for cognitive composites and hippocampal atrophy in imaged cognitively normal adults 
with high Aβ-amyloid. Group slopes for cognitive composites (presented in SD/year) and hippocampal atrophy 
(presented in cm3/year) in imaged cognitively normal adults with high Aβ-amyloid (n = 145). *p < 0.05 when 
comparing to the APOE ε4-ve/KIBRA T carrier group, ^p < 0.05 when comparing to the APOE ε4-ve/KIBRA 
non-T carrier group, ϕ p < 0.05 when comparing to the APOE ε4 + ve/KIBRA T carrier. †q < 0.05 for those 
reporting nominal significance at p < 0.05.
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Our findings indicate that KIBRA rs17070145 genotype, when combined with high brain Aβ-amyloid bur-
den and APOE ε4 carriage, modifies longitudinal rates of decline in verbal episodic memory, a global cognitive 
composite and hippocampal volume. We propose that early in the disease process of AD, carriers of the KIBRA 
T-allele are conferred a level of resilience to Aβ-amyloid and APOE ε4 driven decline. The potential mechanisms 
by which KIBRA contributes to synaptic plasticity, and AD progression warrant further investigation, including 
the potential impact on Aβ-amyloid accumulation, and may reveal novel pathways contributing to neuropro-
tection/neurodegeneration. Our results also highlight the potential application of genetics for risk stratification 
when designing clinical trials, particularly those that employ Aβ-amyloid imaging for screening. The nature of the 
effects of genetic variations, specifically assessing the combined effect(s) of additional genes affecting cognitive 
performance would have merit in such settings and requires further investigation.
Methods
Participants. This study included 602 CN Caucasian adults enrolled in the AIBL Study, a prospective longi-
tudinal study of ageing. Information regarding the AIBL Study’s design, enrolment process, neuropsychological 
assessments, and diagnostic criteria has been previously described34. The clinical classification of CN, MCI or 
AD was determined, after clinical review, by a panel of old age psychiatrists, geriatricians, neurologists, and neu-
ropsychologists who were blinded to Aβ-amyloid status. Individuals were classified as CN if they did not meet 
the clinical criteria for diagnosis of MCI44 or dementia45, as described previously34. Approval of the AIBL Study 
has been granted by each of the ethics committees of each of the member institutions; Austin Health, St Vincent’s 
Health, Hollywood Private Hospital, and Edith Cowan University, and informed written consent was given by all 
volunteers. All clinical investigations were conducted in accord with the principles expressed in the Declaration 
of Helsinki 1975. All participants were assessed every 18-months. Cognitive, neuroimaging and laboratory assess-
ment were acquired within 3-months of each other.
Cognitive Measures. The neuropsychological test battery administered in the AIBL study has been 
described in detail previously34. Briefly, it incorporates at each 18-month follow-up, the Mini-Mental State 
Examination (MMSE), Clock Drawing Test, California Verbal Learning Test-Second edition (CVLT-II), Logical 
Memory I and II (LMI; LMII; Story A only), D-KEFS verbal fluency, a 30-item version of the Boston Naming Test 
(BNT), Wechsler Test of Adult Reading (WTAR) for premorbid IQ, Digit Span and Digit Symbol-Coding subtests 
of the Wechsler Adult Intelligence Scale-Third edition (WAIS-III), the Stroop task (Victoria version), and the 
Rey Complex Figure Test (RCFT). Resultant data from this battery, in addition to the Clinical Dementia Rating 
(CDR), have been previously used to statistically derive cognitive composites as previously described46. In this 
study, a verbal episodic memory composite (CDR sum of boxes (CDRSB), LMII, CVLT false positives (CVLTFP) 
and long delay free recall (CVLTLDFR)), and a statistically driven global composite (CDRSB, MMSE, LMII, CVLTFP 
and Clock), aimed as a sensitive measure for longitudinal decline in individuals predisposed to AD46, were inves-
tigated across five study time points: baseline, 18, 36, 54 and 72 months. A correction for age, gender, years of 
education, WTAR-estimated premorbid IQ (WAIS-III Full Scale Intelligence Quotient (FSIQ)) and depressive 
symptoms (Geriatric Depression Scale (GDS)) was incorporated in the calculation of the cognitive composites47.
Brain Imaging. The 602 CN adults included in this study had undergone Aβ-amyloid imaging, at varying 
time points, with PET using 11C-Pittsburgh Compound B (PiB), 18F-florbetapir or 18F-flutemetamol as previously 
described48–50. PET standardized uptake value (SUV) ratio (SUVR) data was determined for all tracers using 
using CapAIBL, a web based freely availably MR-less methodology51. Briefly, SUVs were summed and normal-
ized to either the cerebellar cortex SUV (PiB), whole cerebellum SUV (florbetapir) or pons SUV (flutemetamol) 
to yield the target-region to reference-region SUVR. These SUVRs were then classified as either low (Αβlow) or 
high (Αβhigh) Aβ-amyloid burden, based on a tracer-specific SUVR threshold; ≥ 1.5, ≥ 1.10 and ≥ 0.62 for PiB, 
florbetapir and flutemetamol, respectively, as previously described52. Of these 602 participants, 548 also under-
went clinical magnetic resonance imaging (MRI) for clinical screening and co-registration with PET images. MRI 
parameters have been described in detail previously53. Briefly, a 3 T T1-weighted MRI was performed using the 
ADNI magnetization-prepared rapid gradient echo protocol, with an in-plane resolution of 1 × 1 mm and a slice 
thickness of 1.2 mm. Hippocampal volume was calculated after correcting for age in years and intracranial vol-
ume, defined as the sum of grey matter, white matter and cerebrospinal fluid volumes, as previously described35.
Genotyping. DNA extraction from 5 mL of whole blood was performed using QIAamp DNA Blood Maxi 
Kits (Qiagen, Hilden, Germany) according to manufacturer’s instructions. TaqMan® genotyping assays were 
used to determine APOE (rs7412, assay ID: C____904973_10; rs429358, assay ID: C___3084793_20) and KIBRA 
(rs17070145, assay ID: C__33286269_10) genotypes (Life Technologies, Carlsbad, CA). All TaqMan® genotyping 
assays were performed on a QuantStudio 12 K Flex™ Real-Time-PCR systems (Applied Biosystems, Foster City, 
CA) using the TaqMan® GTXpress™ Master Mix (Life Technologies) methodology as per manufacturer instruc-
tions. KIBRA genotype was observed not depart from Hardy-Weinberg equilibrium. For the purpose of this 
study APOE carrier status is defined by the presence (1 or 2 copies) or absence (0 copies) of the APOE ε4 allele, 
henceforth referred to as APOE ε4 + ve or APOE ε4-ve, respectively.
Statistical Analyses. All statistical analyses were performed using Rstudio (Rstudio Team 2015) Version 
0.98.1103 for Macintosh54. All analyses were performed based on a dominant model for the KIBRA rs17070145-T 
(minor) allele, i.e. T carrier (i.e. C_T and T_T) compared with non-T carrier (i.e. C_C), as per previous stud-
ies12,18–21,24. Baseline demographic data analyses provided means, standard deviations, and percentages across the 
entire PET imaged cognitively normal sample and stratified by KIBRA rs17070145-T allele carrier (KIBRA-T) 
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and non-carrier (KIBRA non-T) status. ANOVA (age, premorbid IQ, depressive symptoms) and chi-squared tests 
(gender, years of education, APOE ε4 + ve, high Aβ-amyloid burden) were used to determine the significance of 
differences between allelic groups. To determine differences in rates of cognitive change and hippocampal atro-
phy random intercepts linear mixed-effects (LME) models were performed using the “nlme” package in R. LMEs 
were performed due to their ability to model fixed and random effects, and their robustness when dealing with 
missing data55.
After the inclusion of main effects within the model, i.e. KIBRA genotype, interaction terms and covariates 
were included and modelled as described here. Specifically, to investigate the effect of KIBRA on the rate of cog-
nitive decline and hippocampal atrophy, initially a KIBRA × Time interaction was modelled across the entire 
sample, covarying for APOE ε4 carrier and Aβ-amyloid status, with the cognitive composites and hippocampal 
volume as the dependent variables. The effect of Aβ status in combination with KIBRA was then investigated 
by separately modelling an Aβ × KIBRA × Time interaction, co-varying for APOE ε4 carrier status. The third 
analysis focused on only Αβhigh participants, with APOE included within an APOE × KIBRA × Time interaction. 
In addition, all analyses for hippocampal atrophy co-varied for gender. Graphical representations of all models 
are presented with time dependent standard error. Further, for all analyses correction for the False Discovery 
Rate (FDR) using Q-Value (bootstrap method) was performed56. Finally, chi-squared analyses were performed 
between groups to ascertain that group differences in rates of decline were not due to disproportionate rates of 
clinical conversion over the course of the study.
Data availability. All data and samples used in this study are derived from the Australian Imaging, 
Biomarkers and Lifestyle (AIBL) Study of Ageing. All AIBL data, and that specific to this study, is publically 
accessible to all interested parties through an Expression of Interest procedure and is governed by the AIBL Data 
Use Agreement, for more information please see https://aibl.csiro.au/awd/.
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